Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3001-3020 of 3,900 trials

Pediatric Hip Surgery: Tranexamic Acid Study

We are testing whether tranexamic acid can reduce blood loss during hip surgeries in children. This study aims to see if it helps improve recovery and reduces the need for blood transfusions.

Slipped Capital Femoral Epiphysis (SCFE)Legg-Calvé-Perthes Disease (LCPD)Neuromuscular ConditionsMonitoring phase (IV)Standard MedicinesOrthopedics and TraumatologyPediatrics

Non-Small Cell Lung Cancer: Chemotherapy Plus Osimertinib Study

We are evaluating if adding osimertinib to standard chemotherapy helps patients with advanced non-small cell lung cancer who have progressed after initial osimertinib treatment. This study compares the new treatment approach to chemotherapy with a placebo.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesOncology

KIN-2787: New Oral Drug for Cancer

We are studying the safety and effects of KIN-2787 in patients with BRAF and/or NRAS mutation-positive solid tumors. This research aims to find out how well this new treatment works.

Tumors with BRAF and NRAS Mutations>2 yearsSafety phase (I)Oncology

HER2 Positive Metastatic Breast Cancer: ES2B-C001 Study

We are assessing the safety of a new treatment called ES2B-C001, with or without Montanide, for patients with HER2 expressing metastatic breast cancer. This trial aims to understand how safe this new approach is for patients.

HER2 Positive Breast Cancer1-2 yearsSafety phase (I)Oncology

Metastatic Pancreatic Cancer: 5-FU with NALIRI or NALIRINOX

We are studying two new treatment combinations for patients with metastatic pancreatic ductal adenocarcinoma who have progressed after prior therapies. The aim is to see if these combinations improve survival and are safe to use.

Metastatic Pancreatic CancerEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Knee Osteoarthritis: Bovine vs. Marine Chondroitin Sulfate

We are comparing two types of chondroitin sulfate tablets to see if they help reduce pain and improve function in people with knee osteoarthritis. This study will also look at how these treatments affect quality of life and safety.

Knee Osteoarthritis6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOrthopedics and TraumatologyRheumatology

TAR-0520 Gel for Folliculitis in Colorectal Cancer Patients

We are testing a new gel to see if it is safe and effective for preventing skin irritation in patients using EGFR inhibitors for colorectal cancer. This study focuses on its use on the face and chest.

Papuloerythematous Drug EruptionEGFR Inhibitor-Induced Folliculitis1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementDermatologyOncology

Chronic Lymphocytic Leukemia: CAP-100 Treatment

We are testing a new treatment called CAP-100 for patients with relapsed or refractory chronic lymphocytic leukemia. The study aims to assess how safe and tolerable this treatment is.

B-cell Chronic Lymphocytic LeukemiaSafety phase (I)HematologyOncology

Pegcetacoplan for Adolescents with Paroxysmal Nocturnal Hemoglobinuria

We are studying the safety and biological activity of pegcetacoplan in patients aged 12-17 with PNH. This trial will help us understand how well the treatment works and its effects on health-related quality of life.

Paroxysmal Nocturnal Hemoglobinuria3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematology

Chronic Urticaria: Testing Remibrutinib

We are exploring whether remibrutinib can help adults with Chronic Urticaria manage their symptoms better than a placebo. The study also looks at the safety of this new treatment and its effects on quality of life.

Chronic Urticaria≤3 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteAllergologyDermatology

Gastric Cancer Treatment: GASTRICHIP Trial

We are comparing two surgical treatments for advanced gastric cancer to see if adding chemotherapy during surgery improves survival rates. This study involves patients with specific stages of gastric adenocarcinoma.

Stomach Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology

Complicated Urinary Tract Infections in Children: Vabomere Study

We are studying the safety and effectiveness of Vabomere for children aged 3 months to under 12 years with complicated urinary tract infections. This research aims to improve treatment options for these young patients.

Complicated Urinary Tract InfectionAcute Pyelonephritis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesUrology

Alzheimer’s Disease: KarXT for Psychosis

We are testing a new treatment called KarXT for people with psychosis associated with Alzheimer’s disease. The study aims to see if it can reduce symptoms like hallucinations and delusions compared to a placebo.

Psychosis Associated with Alzheimer's Disease3-6 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Group B Streptococcus Vaccine: GBS NN/NN2 in Pregnant Women

We are studying the GBS NN/NN2 vaccine to see how long the immune response lasts and how safe it is when given as a booster during a new pregnancy. We also want to understand how well antibodies are passed from mothers to their babies.

Group B Streptococcus Neonatal Sepsis>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboGynecology and ObstetricsInfectious Diseases

Stage IIIA/B NSCLC: New Immunotherapy and Chemotherapy Approach

We are studying a new treatment combining immunotherapy and chemotherapy for patients with resectable stage IIIA/B non-small cell lung cancer. The trial aims to see if this approach improves survival and quality of life compared to standard treatments.

Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Genital Herpes: IM-250 Treatment Study

We are investigating a new medication, IM-250, for people with recurrent genital herpes to see if it can help reduce outbreaks. The study will also look at the safety of this treatment when given weekly.

Genital Herpes≤3 monthsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementDermatologyInfectious Diseases

Heart Health: Treatment for Frequent PVCs

We are studying whether treating asymptomatic patients with frequent PVCs can prevent future heart function problems. This trial compares treatment options to simple monitoring to see which is more effective.

Premature Ventricular Contractions (PVCs)>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Post-COVID-19 Condition: Plitidepsin Study

We are investigating whether plitidepsin can improve health outcomes for adults with post-COVID-19 Condition. The study will compare its effects to a placebo on symptoms and overall well-being.

Post-COVID-19 Syndrome3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteCardiologyDiabetologyEndocrinologyGastroenterologyHematologyInfectious DiseasesInternal MedicineNeurologyPsychiatryPulmonologyRheumatology

Acute Bacterial Skin Infections: IV Oritavancin for Kids

We are studying a single-dose intravenous medication for children with acute bacterial skin infections. The trial aims to assess its safety and how well it works compared to existing treatments.

Acute Bacterial Skin and Skin Structure Infection>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyPediatrics

Soft Tissue Sarcoma: Trabectedin with tTF-NGR

We are studying a new treatment combining trabectedin with tTF-NGR for patients with advanced soft tissue sarcoma. The goal is to see if this combination helps patients live longer without disease progression compared to trabectedin alone.

Metastatic Soft-Tissue Sarcoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteOncology